Test Strip Market Size and Share
Test Strip Market Analysis by Mordor Intelligence
The Test Strip Market size is estimated at USD 16.69 billion in 2025, and is expected to reach USD 20.18 billion by 2030, at a CAGR of 3.87% during the forecast period (2025-2030). The trajectory reflects a sector balancing the gradual contraction of glucose-only demand against rising sales in multi-analyte, preventive, and home-based diagnostics. Blood glucose strips still represent the largest revenue pool, yet the swift uptake of urine panels, ketone checks, and pregnancy assays signals broader clinical utility. Regionally, North America anchors current revenue while Asia-Pacific supplies incremental volume growth, powered by rising diabetes prevalence and digital health adoption. Competitive intensity remains moderate as established brands respond to continuous glucose monitoring (CGM) cannibalization with technology upgrades and bundled digital ecosystems. Strategic risk centers on enzyme-coated substrate supply chains, although recombinant alternatives promise cost and quality gains.
Key Report Takeaways
- By product, blood strips led with 71.34% revenue share in 2024, while urine strips are projected to advance at a 5.13% CAGR to 2030.
- By application, diabetes maintained 65.85% share of the test strip market size in 2024, whereas urinary tract infection screening is expanding at a 4.64% CAGR through 2030.
- By end user, the homecare segment captured 49.34% of the test strip market share in 2024 and is progressing at a 4.12% CAGR.
- By distribution channel, retail pharmacies held 61.13% of the test strip market size in 2024; online pharmacies register the fastest growth at 4.93% CAGR.
- North America dominated with 38.18% revenue share in 2024, yet Asia-Pacific will record the highest regional CAGR at 5.34% through 2030.
Global Test Strip Market Trends and Insights
Drivers Impact Analysis
Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Surging Global Diabetes Prevalence | +0.8% | Global, with highest impact in Asia-Pacific and Middle East | Long term (≥ 4 years) |
Preference Shift to Point-Of-Care Diagnostics | +0.6% | North America & EU, expanding to emerging markets | Medium term (2-4 years) |
Continuous Technology Upgrades in Enzymatic Chemistries | +0.4% | Global, led by developed markets | Medium term (2-4 years) |
Smartphone-Enabled Optical Strip Readers Gain Regulatory Green-Lights | +0.3% | North America & EU initially, global rollout | Short term (≤ 2 years) |
Expanded Applications - UTIs, Pregnancy, etc. | +0.5% | Global, with faster adoption in developed markets | Medium term (2-4 years) |
Supportive Healthcare Policies and Awareness | +0.4% | Global, varying by healthcare system maturity | Long term (≥ 4 years) |
Source: Mordor Intelligence
Surging Global Diabetes Prevalence
International Diabetes Federation models indicate that 783.2 million adults will have diabetes by 2045, up 46% from 2021 numbers.[1]Source: Sun Hong et al., “IDF Diabetes Atlas,” cdc.gov This epidemiological swell secures a large addressable base for self-monitoring tools. While higher caseloads support the test strip market, CGM uptake in high-income countries tempers per-patient strip volumes, with German data showing 40% usage declines post CGM initiation. This cannibalization effect suggests that while diabetes prevalence drives overall market expansion, the per-patient consumption of traditional test strips may decline in developed markets with high CGM penetration.
Preference Shift to Point-Of-Care Diagnostics
Point-of-care (POC) testing is growing annually, reinforcing healthcare moves toward decentralized, rapid results. FDA clearance of a hepatitis C RNA POC test and expanding EHR integrations,[2]Source: U.S. Food and Drug Administration, “FDA permits marketing of first POC hepatitis C RNA test,” fda.gov such as Abbott’s Epic linkage, strengthen clinical confidence in strip-based assays. The trend particularly benefits urine test strips for UTI screening, where 20 commercially available POC tests now provide results within hours compared to traditional 24-48 hour culture methods.
Continuous Technology Upgrades in Enzymatic Chemistries
Enzymatic chemistry innovations drive test strip accuracy improvements and expand measurable analyte ranges, with glucose dehydrogenase-based systems offering enhanced specificity over traditional glucose oxidase methods. Transition from glucose oxidase to dehydrogenase enhances specificity, while recombinant horseradish peroxidase secures supply continuity and cost stability. Microfluidics have dropped blood volume needs to 0.25 microliters as shown in the POGO Automatic system, lifting adherence among pediatric and geriatric populations. These technological advances support premium pricing strategies while improving patient compliance through reduced discomfort and enhanced convenience.
Smartphone-Enabled Optical Strip Readers Gain Regulatory Green-Lights
Smartphone convergence is progressing through patented optical technologies that address accuracy concerns and provide consumer-friendly analytics. FDA clearance of a home sexually transmitted infection test and AI-enhanced glucose apps confirms regulatory acceptance of mobile-linked strip readers. Digital integration enables advanced data analytics and AI-powered insights, as exemplified by Dexcom's generative AI platform that provides personalized glucose management recommendations.
Restraints Impact Analysis
Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Sparse Reimbursement for OTC Strip Purchases | -0.7% | Global, most severe in emerging markets | Medium term (2-4 years) |
Accuracy Concerns Versus Lab-Based Reference Tests | -0.4% | Global, regulatory scrutiny highest in developed markets | Short term (≤ 2 years) |
Enzyme-Coated Substrate Supply Volatility | -0.3% | Global, supply chain concentrated in Asia | Short term (≤ 2 years) |
CGM Uptake Cannibalising Glucose-Strip Volumes | -0.9% | Developed markets initially, expanding globally | Long term (≥ 4 years) |
Source: Mordor Intelligence
Sparse Reimbursement for OTC Strip Purchases
Coverage gaps limit retail uptake, particularly among non-insulin users who receive only 100 strips per quarter under United States Medicare guidelines.[3]Source: American Diabetes Association, “Medicare,” diabetes.org Emerging economies face heavier out-of-pocket burdens, prompting domestic innovators like Morepen Labs to push low-priced meters for India’s potential 100 million diabetic population. The reimbursement gap particularly affects continuous monitoring adoption, where CGM devices receive coverage while traditional strips face increasing restrictions, creating a bifurcated market where insured patients migrate to CGM while uninsured populations rely on cost-constrained traditional testing.
CGM Uptake Cannibalising Glucose-Strip Volumes
Germany reports daily strip use halved after intermittent CGM adoption, and FDA clearance of the first OTC CGM in 2024 broadens the substitution threat. Abbott’s Libre Rio launch targets wellness consumers, further diverting demand away from traditional strips. The cannibalization effect varies by patient segment, with insulin-dependent users showing higher CGM adoption rates while cost-sensitive populations maintain strip dependency, creating a market stratification that challenges traditional volume projections.
Segment Analysis
By Product: Blood Strips Dominate Despite Urine Growth
Blood glucose strips generated 71.34% of 2024 revenue for the test strip market, anchored by entrenched therapeutic guidelines and insurance coverage. The segment benefits from enzymatic refinements that enable 0.5 microliter samples and 7-second reads, showcased by ARKRAY’s GLUCOCARD Vital platform. Yet, urine panels are expanding at a 5.13% CAGR as healthcare providers promote early screening for urinary tract infections, kidney disease, and pregnancy. ARKRAY’s 11-parameter AUTION line illustrates the multi-analyte advantage, encouraging physicians to replace single-purpose strips with comprehensive urinalysis.
Growth momentum in urine diagnostics hinges on preventive medicine trends. Digital telehealth platforms in urban China integrate home urine strips with cloud analytics, enabling remote physician oversight and medication adherence tracking. Blood-strip makers counter by embedding Bluetooth and EHR connectivity to preserve relevance.
By Application: Diabetes Leadership Faces UTI Challenge
Diabetes care produced 65.85% of 2024 revenue for the test strip market, yet its growth is moderating to 3.1% annually as CGM substitution accelerates in high-income markets. Conversely, urinary tract infection screening is accelerating at 4.64% CAGR, supported by primary-care protocols that favor rapid POC urinalysis to curb antibiotic misuse. Pregnancy testing maintains steady demand, aided by dual fertility functions and smartphone readers that improve result interpretation.
Clinical guidelines recommending quarterly HbA1c POC tests extend strip-based HbA1c opportunities in both urban and rural China, where cost-utility ratios fall well below local GDP per capita thresholds. The test strip industry also witnesses crossover innovation. Researchers adapted glucometers to quantify SARS-CoV-2 antibodies, proving the platform’s flexibility for future multiplex infectious disease panels.
By End User: Homecare Dominance Reflects Patient Empowerment
Home users accounted for 49.34% of revenue in 2024 and will continue outpacing institutional channels. Simplified sample handling, automated lancet-strip combinations, and mobile dashboards give consumers real-time decision support. Medicare’s mail-order program further cements home supply continuity. POGO Automatic’s integrated cartridge system exemplifies friction-free operation, drawing adoption among tech-savvy younger cohorts.
Hospitals and clinics remain vital for complex case management and perioperative monitoring. BD’s MiniDraw fingertip device delivers venous-equivalent results, strengthening the case for strip-based assays in acute settings. Diagnostic laboratories leverage high-throughput auto-readers for chronic disease panels, yet their share erodes as payers favor decentralized care models.

Note: Segment shares of all individual segments available upon report purchase
By Distribution Channel: Retail Pharmacy Strength Meets Online Growth
Retail pharmacies held 61.13% of the test strip market in 2024 due to immediate availability and pharmacist counseling. Loyalty programs and Medicare copay handling preserve foot traffic. Online pharmacies, however, are scaling 4.93% annually through subscription refills, predictive shipping algorithms, and lower overhead costs. Direct-to-consumer models provide manufacturers with margin gains and data insights that inform future device design.
Regulatory continuity assists both channels. The FDA’s Laboratory Developed Test rule creates unified quality expectations and stabilizes distribution planning through a four-year phase-in. Retailers and e-commerce operators alike align with emerging Unique Device Identifier requirements, facilitating recalls and counterfeit mitigation.
Geography Analysis
North America generated 38.18% of 2024 revenue for the test strip market, enabled by well-established insurance coverage and widespread chronic disease management programs. Medicare’s 300-strip quarterly limit for insulin users ensures baseline demand, and the 2024 USD 35 insulin copay cap frees consumer cash for ancillary supplies. Yet, CGM expansion moderates volume growth as Abbott and Medtronic push OTC sensors to retail shelves. Federal Laboratory Developed Test policy changes introduce predictable compliance pathways, encouraging multinational entrants to sustain investment.
Asia-Pacific delivers the fastest regional CAGR at 5.34%, driven by climbing diabetes prevalence, urban dietary shifts, and expanding middle-class purchasing power. China’s integrated digital management initiatives cut average fasting glucose by 1.68 mmol/L in Tianjin pilots, underscoring demand for connected home testing. India’s domestic manufacturing scale-up from 2.5 million to 5 million glucometers annually lifts supply resilience, while lower per-capita income keeps price elasticity high. Point-of-care HbA1c screening in rural China also proves cost-effective, demonstrating the appeal of compact strip readers in resource-constrained settings.
Europe sustains moderate expansion under the In Vitro Diagnostic Regulation transitional timelines to 2027-2029, which maintain device availability during recertification. Partnership-led growth emerges as A. Menarini secures exclusive Sinocare CGM rights across more than 20 jurisdictions, blending continuous and strip-based portfolios. Meanwhile, Middle East, Africa, and South America represent nascent demand pools where limited reimbursement favors low-priced strips over premium CGM hardware.

Competitive Landscape
Competition in the test strip market shows moderate fragmentation. Abbott, Roche, and LifeScan control leading channel relationships and invest in integrated ecosystems to offset CGM substitution. Abbott’s Libre data feed into Epic electronic records locks in provider loyalty, while Roche released an AI-enabled CGM predictive tool to keep engagement high. LifeScan leverages OneTouch Reveal cloud analytics to maintain relevance despite shrinking strip volumes.
Mid-tier players differentiate through multi-parameter innovation. ARKRAY pairs blood and urine lines with temperature correction features that boost accuracy across climate zones. Siemens Healthineers integrates strip autoloaders into lab informatics suites, bridging point-of-care and core-lab workflows. Regional specialists such as Sinocare scale cost-advantaged production for emerging markets, while Morepen Labs expands domestically to meet Indian demand peaks.
Supply chain strategy is an emerging competitive metric. Vienna University of Technology’s E.coli-derived horseradish peroxidase opens licensing opportunities to reduce agriculture risk. Companies securing such bioprocessing know-how gain margin and risk advantages. Strategic moves also include portfolio rationalization: Asahi Kasei divested certain diagnostics lines to concentrate on high-growth segments. Partnerships, such as Abbott–Medtronic data-sharing agreements, highlight a broader shift toward ecosystem interoperability that blurs company boundaries.
Test Strip Industry Leaders
-
ARKRAY, Inc.
-
Ascensia Diabetes Care Holdings AG
-
Abbott
-
F. Hoffmann-La Roche
-
LifeScan
- *Disclaimer: Major Players sorted in no particular order

Recent Industry Developments
- November 2024: Beurer India launched the GL 22 Blood Glucose Monitor along with companion strips.
- October 2024: Trividia Health TRUE METRIX strip line gained preferred status across all Florida Managed Medicaid plans.
- June 2024: Researchers at India’s National Institute of Technology Raipur created a urine-based glucose strip that may remove finger-prick barriers.
- April 2024: OVUM launched the nation's first fully recyclable early-detection pregnancy tests. Its products are sold in Sainsbury's stores across the United Kingdom. OVUM's B Corp certification highlights its commitment to environmental and social responsibility. This focus on sustainability, alongside its innovative products, is expected to resonate with eco-conscious consumers.
Global Test Strip Market Report Scope
As per the scope of the report, a test strip is a key component of blood glucose testing and urinalysis. It is used to monitor or control a diabetic patient's blood glucose level. It allows people who are pre-diabetic or diabetic to monitor their blood glucose levels regularly without going to a clinic or a diagnostic laboratory.
The test strip market is segmented by product (blood test strips and urine test strips), application (diabetes, pregnancy, urinary tract infection, and other applications), end user (hospitals, home care, and diagnostic laboratories), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers market sizes and forecasts in terms of value (USD) for the above-mentioned segments.
By Product | Blood Test Strips | ||
Urine Test Strips | |||
By Application | Diabetes | ||
Pregnancy Detection | |||
Urinary Tract Infection | |||
Other Applications | |||
By End User | Hospitals & Clinics | ||
Homecare / Personal Use | |||
Diagnostic Laboratories | |||
By Distribution Channel | Hospital Pharmacies | ||
Retail Pharmacies | |||
Online Pharmacies | |||
By Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia-Pacific | China | ||
Japan | |||
India | |||
Australia | |||
South Korea | |||
Rest of Asia-Pacific | |||
Middle East and Africa | GCC | ||
South Africa | |||
Rest of Middle East and Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
Blood Test Strips |
Urine Test Strips |
Diabetes |
Pregnancy Detection |
Urinary Tract Infection |
Other Applications |
Hospitals & Clinics |
Homecare / Personal Use |
Diagnostic Laboratories |
Hospital Pharmacies |
Retail Pharmacies |
Online Pharmacies |
North America | United States |
Canada | |
Mexico | |
Europe | Germany |
United Kingdom | |
France | |
Italy | |
Spain | |
Rest of Europe | |
Asia-Pacific | China |
Japan | |
India | |
Australia | |
South Korea | |
Rest of Asia-Pacific | |
Middle East and Africa | GCC |
South Africa | |
Rest of Middle East and Africa | |
South America | Brazil |
Argentina | |
Rest of South America |
Key Questions Answered in the Report
What is the projected value of the test strip market in 2030?
The test strip market is forecast to reach USD 20.18 billion by 2030 based on a 3.87% CAGR.
Which product segment is growing fastest?
Urine test strips are the fastest-growing segment, expanding at a 5.13% CAGR as healthcare shifts toward preventive screening.
How is CGM adoption affecting traditional strip demand?
In developed markets, CGM users cut daily strip use nearly in half, leading to a −0.9% impact on overall CAGR despite rising diabetes incidence.
Which region will contribute most to incremental growth?
Asia-Pacific will supply the largest share of new volume, with a 5.34% regional CAGR driven by rising prevalence and digital health programs.
What role do retail pharmacies play in distribution?
Retail pharmacies account for 61.13% of 2024 revenue, but online channels are growing faster at 4.93% CAGR due to subscription refill models.
Page last updated on: June 30, 2025